.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Baxter
Harvard Business School
UBS
Healthtrust
McKinsey
Teva
Federal Trade Commission
Citi
Daiichi Sankyo

Generated: November 17, 2017

DrugPatentWatch Database Preview

Hq Spclt Pharma Company Profile

« Back to Dashboard

What is the competitive landscape for HQ SPCLT PHARMA, and when can generic versions of HQ SPCLT PHARMA drugs launch?

HQ SPCLT PHARMA has six approved drugs.

There are four US patents protecting HQ SPCLT PHARMA drugs.

There are forty patent family members on HQ SPCLT PHARMA drugs in twenty-five countries and twenty-seven supplementary protection certificates in ten countries.

Summary for Hq Spclt Pharma

International Patents:40
US Patents:4
Tradenames:9
Ingredients:6
NDAs:6
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hq Spclt Pharma
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER
esmolol hydrochloride
SOLUTION;INTRAVENOUS205703-001Apr 7, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Hq Spclt Pharma
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER
esmolol hydrochloride
SOLUTION;INTRAVENOUS205703-002Apr 7, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Hq Spclt Pharma
LINEZOLID
linezolid
SOLUTION;IV (INFUSION)207001-001Jul 7, 2017APRXNoNo► Subscribe► Subscribe► Subscribe
Hq Spclt Pharma
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER
esmolol hydrochloride
SOLUTION;INTRAVENOUS205703-001Apr 7, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Hq Spclt Pharma
PLATINOL-AQ
cisplatin
INJECTABLE;INJECTION018057-003Jul 18, 1984DISCNYesNo► Subscribe► Subscribe► Subscribe
Hq Spclt Pharma
PLATINOL
cisplatin
INJECTABLE;INJECTION018057-002Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Hq Spclt Pharma
DEXMEDETOMIDINE HYDROCHLORIDE
dexmedetomidine hydrochloride
SOLUTION;IV (INFUSION)206628-001Oct 21, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Hq Spclt Pharma
DEXMEDETOMIDINE HYDROCHLORIDE
dexmedetomidine hydrochloride
SOLUTION;IV (INFUSION)206628-002Oct 21, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Hq Spclt Pharma
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER
esmolol hydrochloride
SOLUTION;INTRAVENOUS205703-002Apr 7, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Hq Spclt Pharma
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER
esmolol hydrochloride
SOLUTION;INTRAVENOUS205703-002Apr 7, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Hq Spclt Pharma

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Hq Spclt Pharma
PLATINOL
cisplatin
INJECTABLE;INJECTION018057-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Hq Spclt Pharma
CISPLATIN
cisplatin
INJECTABLE;INJECTION018057-004Nov 8, 1988► Subscribe► Subscribe
Hq Spclt Pharma
PLATINOL
cisplatin
INJECTABLE;INJECTION018057-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Hq Spclt Pharma
PLATINOL-AQ
cisplatin
INJECTABLE;INJECTION018057-003Jul 18, 1984► Subscribe► Subscribe
Hq Spclt Pharma
TAXOL
paclitaxel
INJECTABLE;INJECTION020262-001Dec 29, 1992► Subscribe► Subscribe
Hq Spclt Pharma
TAXOL
paclitaxel
INJECTABLE;INJECTION020262-001Dec 29, 1992► Subscribe► Subscribe
Hq Spclt Pharma
TAXOL
paclitaxel
INJECTABLE;INJECTION020262-001Dec 29, 1992► Subscribe► Subscribe
Hq Spclt Pharma
PLATINOL
cisplatin
INJECTABLE;INJECTION018057-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Hq Spclt Pharma
CISPLATIN
cisplatin
INJECTABLE;INJECTION018057-004Nov 8, 1988► Subscribe► Subscribe
Hq Spclt Pharma
PLATINOL-AQ
cisplatin
INJECTABLE;INJECTION018057-003Jul 18, 1984► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Hq Spclt Pharma Drugs

Country Document Number Estimated Expiration
MexicoPA03006229► Subscribe
TaiwanI277414► Subscribe
Slovakia288113► Subscribe
China1981739► Subscribe
Czech Republic20023825► Subscribe
European Patent Office1738756► Subscribe
Australia2002309475► Subscribe
Russian Federation2002132189► Subscribe
China1455669► Subscribe
Slovakia12782002► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Hq Spclt Pharma Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014022Lithuania► SubscribePRODUCT NAME: PACLITAXELUM; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220
12/048Ireland► SubscribePRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812
00117Netherlands► SubscribePRODUCT NAME: DEXMEDETOMIDINE, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH IN FARMACEUTISCH OPZICHT AANVAARDBAAR ZUURADDITIEZOUT, IN HET BIJZ ONDER DEXMEDETOMIDINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/2/02/033/001 20020830
2012 00035Denmark► SubscribePRODUCT NAME: ET KOMBINATIONSPRODUKT AF NAPROXEN OG ESOMEPRAZOL MAGNESIUM TRIHYDRAT; NAT. REG. NO/DATE: 49583 20120327; FIRST REG. NO/DATE: GB PL 17901/0263-001 20101105
00482Netherlands► SubscribePRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMZOUT; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17091/0263 - 0001 20101105
00615Netherlands► SubscribePRODUCT NAME: NATRIUMSULFAAT, MAGNESIUMSULFAAT EN KALIUMSULFAAT; NAT. REGISTRATION NO/DATE: RVG 110863 20130417; FIRST REGISTRATION: BE 434323 20130220
90006-4Sweden► SubscribePRODUCT NAME: ACETYLSALICYLSYRA OCH ESOMEPRAZOLMAGNESIUMTRIHYDRAT; NAT. REG. NO/DATE: MTNR 44371 20110930; FIRST REG.: PT 5402359MFL 20110812
00517Netherlands► SubscribePRODUCT NAME: ACETYLSALICYLZUUR EN ESOMEPRAZOLMAGNESIUMTRIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 107516 20110912; FIRST REGISTRATION: 540235954023675402375 2011120812
2004004Lithuania► SubscribePRODUCTNAME: LINEZOLIDUM - (S)-N-[[3-FLUOR-4-(4-MORFOLINIL)FENIL]-2-OKSO-5-OKSAZOLIDINIL]METIL]-ACETAMIDAS
C0055France► SubscribePRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: 434323 20130220
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Accenture
Medtronic
Mallinckrodt
QuintilesIMS
Healthtrust
Covington
Boehringer Ingelheim
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot